We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Sekisui Diagnostics UK Ltd.

Download Mobile App




Experimental Drug Blocks Critical Lung Cancer DNA Repair Enzyme

By LabMedica International staff writers
Posted on 02 Jun 2015
Print article
Image: Structure of the DDX3X protein (Photo courtesy of Wikimedia Commons).
Image: Structure of the DDX3X protein (Photo courtesy of Wikimedia Commons).
A low molecular weight drug—effective on its own and in combination with radiation therapy—has been developed that interferes specifically with the cell cycle of lung cancer cells.

The drug, RK-33, was developed by investigators at Johns Hopkins University (Baltimore, MD, USA) to block the activity of the RNA helicase, DDX3 (DEAD (Asp-Glu-Ala-Asp) box helicase 3, X-linked), which is overexpressed in many cancer types including lung cancer and is associated with lower survival in lung cancer patients.

The main function of helicases is to unpackage an organism's genes. They are motor proteins that move directionally along a nucleic acid phosphodiester backbone, separating two annealed nucleic acid strands (i.e., DNA, RNA, or RNA-DNA hybrid) using energy derived from ATP hydrolysis. There are many helicases due to the great variety of processes in which strand separation must be catalyzed. The human genome codes for 95 non-redundant helicases: 64 RNA helicases and 31 DNA helicases.

DDX3 is a member of the large DEAD-box protein family, which is defined by the presence of the conserved Asp-Glu-Ala-Asp (DEAD) motif, and has ATP-dependent RNA helicase activity. This protein has been reported to display a high level of RNA-independent ATPase activity, and unlike most DEAD-box helicases, the ATPase activity is thought to be stimulated by both RNA and DNA. This protein has multiple conserved domains and is thought to play roles in both the nucleus and cytoplasm. Overexpression of this gene has been implicated in tumor development.

The investigators synthesized the low molecular weight compound RK-33, which was designed to inhibit DDX3 by binding to the nucleotide-binding site within the enzyme. Results published in the May 2015 issue of the journal EMBO Molecular Medicine revealed that RK-33 binding inhibited DDX3's DNA repair function, which caused tumor cells to die and increased the efficacy of radiation therapy. RK-33 in combination with radiation induced tumor regression in multiple mouse models of lung cancer without causing damage to noncancerous tissues.

“We can lower the dose of radiation significantly but actually get more “bang for your buck” by pretreating lung cancer with RK-33,” said senior author Dr. Venu Raman, associate professor of radiology, radiological science, and oncology at Johns Hopkins University. “DDX3 is an extremely novel target associated with many cancer types and perturbing its function with a small molecule will enhance efficacy for cancer treatment. It is hard to find a magic bullet for cancer treatment, but because RK-33 is nontoxic and is a phenomenal radiosensitizer, there are so many opportunities.”

Related Links:

Johns Hopkins University


Gold Member
Blood Gas Analyzer
GEM Premier 7000 with iQM3
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
New
Urine Collection Container
Urine Monovette
New
Silver Member
Rubella Infection ELISA
ReQuest RUBELLA IgM ELISA Kit

Print article

Channels

Clinical Chemistry

view channel
Image: The new saliva-based test for heart failure measures two biomarkers in about 15 minutes (Photo courtesy of Trey Pittman)

POC Saliva Testing Device Predicts Heart Failure in 15 Minutes

Heart failure is a serious condition where the heart muscle is unable to pump sufficient oxygen-rich blood throughout the body. It ranks as a major cause of death globally and is particularly fatal for... Read more

Molecular Diagnostics

view channel
Image: The bowel cancer breakthrough could result in better treatment outcomes (Photo courtesy of 123RF)

New RNA Molecules Can Help Predict Bowel Cancer Return Recurrence

Colorectal cancer accounts for 10% of all cancer-related deaths worldwide and was ranked as the second most common cause of cancer death in the United States in 2022. Currently, clinicians face diagnostic... Read more

Hematology

view channel
Image: QScout CBC will give a complete blood count in 2 minutes from fingerstick or venous blood (Photo courtesy of Ad Astra Diagnostics)

Next Gen CBC and Sepsis Diagnostic System Targets Faster, Earlier, Easier Results

Every hour is critical in protecting patients from infections, yet there are currently limited tools to assist in early diagnosis before patients reach a hospital. The complete blood count (CBC) is a common... Read more

Microbiology

view channel
Image: The InfectoSynovia test has the potential to revolutionize the diagnosis of periprosthetic joint infection (Photo courtesy of 123RF)

High-Accuracy Bedside Test to Diagnose Periprosthetic Joint Infection in Five Minutes

Periprosthetic joint infection (PJI) represents a significant global issue that is worsening as the number of joint replacements increases due to aging populations. In the United States alone, the anticipated... Read more

Pathology

view channel
Image

AI-Based Method Shows Promise for Pathological Diagnosis of Hereditary Kidney Diseases

Alport syndrome is a hereditary kidney disorder characterized by kidney dysfunction, sensorineural hearing loss, and ocular abnormalities. Early in the disease, patients experience hematuria, which is... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.